Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Nanobiotix (NBTX) Analyst Targets Suggest +53% Upside to $47

Nanobiotix (NBTX) Analyst Targets Suggest +53% Upside to $47

Key Takeaways

  • The central stock price target used here is $47, the arithmetic mean of three current, individually verifiable analyst targets ($64, $46, and $30).
  • The latest verified closing price for Nanobiotix S.A. (NBTX) is about $30.66, implying roughly 53% upside to reach the target.
  • The analyst range is unusually wide — $30 to $64 — reflecting the binary, event-driven nature of clinical-stage biotechnology.
  • The strongest support is the company's first-in-class radio-enhancer candidate (JNJ-1900/NBTXR3), its global partnership with Johnson & Johnson's Janssen unit, and a cash runway expected to extend into 2029.
  • The biggest risks are clinical and regulatory execution, reliance on a single lead asset, dilutive capital raises, and continued operating losses.
  • For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
  • Readers can also explore Trending AI Robots to see how AI-driven tools approach this and other tickers.

Analyst Price Targets and Consensus View

Nanobiotix S.A. is a Paris-based, late-stage clinical biotechnology company whose American Depositary Shares (ADSs) trade on Nasdaq under the ticker NBTX. The company develops NBTXR3 — now licensed to Johnson & Johnson's Janssen unit as JNJ-1900 — a hafnium-oxide nanoparticle "radio-enhancer" designed to amplify the effect of radiation therapy on solid tumors.

Coverage of the stock is thin. Three current, individually attributable analyst price targets form the basis of this article's central target:

  • Guggenheim (analyst Paul Jeng): Buy, $64 (coverage assumed September 15, 2026), centered on JNJ-1900's first-in-class radio-enhancer potential.
  • Leerink Partners (analyst Jonathan Chang): Outperform, $46 (raised from $37 on June 4, 2026), citing the late-stage pipeline and partnerships.
  • UBS: Neutral, $30 (raised from $3.50 on May 1, 2026), a more cautious view.

The arithmetic mean of these three targets is $46.67, rounded to $47 for this analysis. The low-to-high range is $30 to $64. Note that aggregators display different "consensus" figures depending on their time windows and whether they include older or unattributed estimates; this article uses only targets tied to a named firm and date. That wide $34 spread between the low and high is itself informative: analysts disagree sharply on how much of the Janssen collaboration's upside is already priced in. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

As of the latest verified close, shares trade near $30.66, with a 52-week range of $19.14 to $57.14 and a market capitalization of roughly $1.56 billion. Reaching $47 would require a gain of about 53% — a very large move, not a marginal nudge. The shares are also well below their prior 52-week high, meaning the target implies a meaningful recovery toward, but not beyond, that earlier peak.

The path to such a move is fundamentally event-driven rather than earnings-driven. Nanobiotix is pre-profitability, with trailing twelve-month revenue of roughly $13 million and a net loss near $60 million, so conventional valuation metrics offer little guidance. Instead, the stock's trajectory hinges on clinical data readouts from the Phase 3 NANORAY-312 head-and-neck cancer study, additional Phase 1 data from Study 1100 in non-small cell lung cancer, and the company's ability to convert the Janssen collaboration into milestone and royalty payments.

What Could Support a Move Toward the Target

  • Differentiated science: JNJ-1900 is positioned as a first-in-class radio-enhancer, and recent data — including a reported 79% local control rate in a lung cancer cohort — has underpinned the sharp upgrades in price targets this year.
  • Deep-pocketed partner: The Janssen agreement includes success-based milestones of up to $1.8 billion, plus tiered double-digit royalties, providing a potential non-dilutive funding source if trials succeed.
  • Strengthened balance sheet: A roughly €85 million global offering completed in May 2026 (about $100 million with the over-allotment) extended the projected cash runway into 2029, reducing near-term dilution overhang.
  • Rising target revisions: All three covering firms raised their targets sharply during 2026 — Guggenheim from $8 to $64 across successive reviews — signaling improving conviction.

What Could Prevent the Target From Being Reached

  • Binary clinical risk: A disappointing or delayed Phase 3 readout could compress the valuation quickly, given the company's dependence on a single lead program.
  • Financing and dilution: As a pre-revenue biotech, Nanobiotix may need additional capital raises, which can weigh on the share price despite the extended runway.
  • Limited, divided coverage: With only three current targets spanning $30 to $64, the "analyst consensus" is fragile; the most cautious view sits essentially at the current price.
  • Partner dependence: Development timelines and milestone payments are controlled largely by Janssen, introducing execution and timing risk outside Nanobiotix's direct control.

Technical Levels and Market Structure

The shares are in a broad range between the 52-week low of about $19.14 and the 52-week high of about $57.14. The $57 area represents a meaningful resistance level from the prior peak, while the $30 zone — coinciding with UBS's target and a round-number psychological level — has acted as a nearby support level. Reaching $47 would first require reclaiming ground between roughly $33 and $40, where the stock has traded in recent months, before testing the upper half of the range toward the prior high.

Time Horizon and What Investors Should Monitor

Analyst price targets for NBTX are typically framed on a roughly 12-month research horizon, though firms do not always disclose a precise date. Investors focused on this target should watch: clinical data readouts and regulatory updates for JNJ-1900, including the NANORAY-312 Phase 3 study and Study 1100; milestone and royalty announcements under the Janssen agreement; semi-annual earnings and cash-position updates; any further analyst target revisions or new coverage initiations; and broader biotech-sector risk appetite, which can lift or depress pre-profitability names regardless of company-specific news.

Exploring AI Tools for Additional Insights

In my view, layering quantitative signals on top of the fundamental story can help clarify timing. One thing that stands out is how AI-driven monitoring can flag shifts in sentiment or technical momentum that pure analyst reports might miss. From what I see, this approach adds context without replacing the need to track clinical catalysts closely.

AI Daily Buy/Sell Signals

AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening allows. For a data-driven complement to fundamental research on names like NBTX, consider exploring these AI-generated signals. I’ve found them useful as a quick cross-check when reviewing event-driven names in biotech.

Final Assessment

The $47 central target represents the average of three current analyst targets ($64, $46, and $30), implying roughly a 53% rise from the latest price near $30.66 — a very large move justified only by successful clinical execution. The bull case rests on differentiated science, a major pharmaceutical partner, and an improved cash runway; the bear case rests on binary trial risk, potential dilution, and the fact that the most cautious analyst sits essentially at today's price. The unusually wide $30-to-$64 range underscores genuine uncertainty. Whether NBTX reaches $47 will likely be determined less by valuation than by the next round of clinical data and how the market interprets it. No definitive outcome can be forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NBTX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NBTX's Stochastic Oscillator stoops into oversold zone

The Stochastic Oscillator for NBTX moved into oversold territory on November 17, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for NBTX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

NBTX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NBTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-46.722) is normal, around the industry mean (3.592). P/E Ratio (-28.101) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
60 Rue de Wattignies
Phone
+33 140260470
Employees
97
Web
https://www.nanobiotix.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.